Executive Summary
Valneva has filed an IPR petition challenging all 67 claims of Takeda’s Zika vaccine patent, asserting anticipation and obviousness over multiple prior‑art references. The petitioner argues the examiner erred and that no discretionary bars apply, seeking cancellation of the entire patent.
Related Cases
Samsung Electronics Co., Ltd. et al.vsNetlist, Inc.
The PTAB held that all challenged claims of Netlist’s ’833 hybrid memory patent are unpatentable, finding them obvious over a combination of Best, Bonella, and Mills. Samsung, as petitioner, prevailed on both claim construction and obviousness grounds.
Aputure Imaging Industries Co., Ltd.vs--
Aputure Imaging and Rotolight settled their IPR disputes covering four patents, leading the PTAB to terminate the proceedings and keep the settlement confidential.
Samsung Electronics Co., Ltd. et al.vsKP INNOVATIONS 2, LLC
The PTAB denied Samsung’s request for Director Review of the institution denial in IPR2025-00101, leaving the original decision unchanged.
Amazon.com, Inc. et al.vsNokia Technologies Oy
Amazon and Nokia settled their IPR dispute over U.S. Patent 9,390,137 before trial. The Board terminated the proceeding and ordered the settlement documents to be kept confidential.
Taiwan Semiconductor Manufacturing Company Limited et al.vsMarlin Semiconductor Ltd. et al.
The PTAB upheld the Director’s discretionary denial of an IPR challenging Marlin Semiconductor’s 2015 metal‑oxide semiconductor transistor patent, citing settled expectations and a parallel ITC investigation. TSMC and Apple’s arguments about size and investment were deemed immaterial.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.